Loading
Old version — revision 1
This is a fixed snapshot of David Sinclair, saved by Import as part of the initial corpus import. It is not edited and it is not updated; the article may have changed since.
Edit summary: Initial import of content/david-sinclair.md — the filesystem corpus, unchanged. Not an edit.
Australian-American biologist at Harvard known for sirtuin and NAD+ research, the information theory of aging, and disputes over the strength of his public claims.
David Sinclair is an Australian-American molecular biologist at Harvard Medical School whose laboratory has worked on yeast aging, sirtuins, NAD+ metabolism and epigenetic rejuvenation. He is among the most publicly visible biogerontologists and the most criticized within the field, with the criticism aimed less at the underlying experiments than at how far his public statements travel beyond them.
Sinclair completed a doctorate in molecular genetics at the University of New South Wales and moved to MIT as a postdoctoral researcher with Leonard Guarente, where he identified extrachromosomal ribosomal DNA circles as a driver of replicative aging in budding yeast.1 He joined Harvard Medical School in 1999 and co-directs the Paul F. Glenn Center for Biology of Aging Research there. He has founded or co-founded a series of companies across the aging sector, including Sirtris Pharmaceuticals, Life Biosciences and the consumer Biological age testing firm Tally Health, and he holds advisory positions across many more.
The sirtuins are NAD+-dependent deacetylases; Guarente's laboratory had linked the yeast homolog SIR2 to lifespan and to the response to Caloric restriction, and the question was whether small molecules could reproduce that response by activating the mammalian equivalents. In 2003 Sinclair's group reported that resveratrol, a polyphenol found in red wine, activated SIRT1 and extended yeast lifespan.2 A 2006 paper reported that resveratrol improved survival in mice fed a high-calorie diet.3 Sirtris was founded on this work and acquired by GlaxoSmithKline in 2008 for a sum in the hundreds of millions of dollars.
The programme then unravelled. Pfizer scientists reported that the apparent SIRT1 activation was an artifact of the fluorophore attached to the assay substrate, and did not occur with native peptides.4 GSK halted development of its resveratrol formulation in 2010 and closed Sirtris in 2013. Sinclair and colleagues have continued to argue that allosteric sirtuin activation is real under the right substrate conditions, and the biochemistry remains disputed. No sirtuin activator has demonstrated an effect on human aging.
ContestedResveratrol's lifespan effects have not replicated consistently in mammals. The US National Institute on Aging's Interventions Testing Program, which tests compounds across three genetically heterogeneous mouse cohorts, did not find a lifespan extension for resveratrol — in contrast to its result for Rapamycin.
Sinclair's laboratory subsequently focused on NAD+ decline with age, reporting that falling nuclear NAD+ disrupts communication with mitochondria and that raising it with precursors reverses aspects of that state in mice.5 This work is part of the case for NAD+ precursors as geroprotectors. Human trials of nicotinamide riboside and nicotinamide mononucleotide have reliably raised blood NAD+ concentrations; they have not demonstrated functional benefit on aging endpoints.
His broader theoretical claim is the information theory of aging: that aging is driven not by the accumulation of DNA mutations but by the progressive loss of epigenetic information — cells forgetting which genes to express — and that the information can in principle be restored because a backup copy persists. The supporting experiment used mice engineered to sustain repeated non-mutagenic DNA double-strand breaks, which accelerated epigenetic and physiological aging markers.6 Critics have argued that repeated double-strand breaks are a severe and non-physiological insult, and that the result shows DNA damage accelerates aging phenotypes rather than that ordinary aging is epigenetic in origin. The distinction matters because the therapeutic programme of resetting the epigenome follows only from the stronger claim, and because the readouts used to demonstrate it are DNA methylation clocks whose causal status is itself disputed. See Epigenetic reprogramming and Hallmarks of aging.
In 2020 his laboratory reported that transient expression of three Yamanaka factors, omitting Myc, restored vision in mice after optic nerve crush and in an aged glaucoma model, with the effect depending on DNA demethylases.7 The paper is among the most cited demonstrations that OSK can improve function in a living mammal without erasing cell identity, and it is a foundational reference for the reprogramming companies, including Altos Labs and NewLimit. It is also a single tissue in a mouse, using an inducible transgenic system rather than a deliverable therapy, and the extrapolation to systemic human rejuvenation is not supported by it.
Sinclair's publication record is substantial and his laboratory's core findings on NAD+ biology and optic nerve reprogramming are taken seriously. The criticism concerns claims made outside the papers. Lifespan (2019) argues that aging is a treatable disease and that readers alive today may benefit; it also describes his personal supplement regimen, which the book's own evidence does not support for humans. Colleagues including the biogerontologist Matt Kaeberlein and the NAD biochemist Charles Brenner have publicly disputed both specific mechanistic claims and the general practice of presenting mouse data in language that implies human results.
The sharpest institutional rupture came in 2024. As president of the Academy for Health and Lifespan Research, Sinclair promoted a canine supplement in terms that other members read as claiming demonstrated age reversal in dogs. A supplement carries no regulatory review of such a claim, unlike the canine lifespan candidates Loyal is taking through the veterinary regulator. Much of the academy's board resigned in protest and Sinclair stepped down as president. The episode is now the standard citation in arguments that the longevity field's credibility problem is self-inflicted.
Where the disagreement actually sitsAlmost nobody disputes that NAD+ falls with age or that OSK expression alters epigenetic marks. The dispute is whether these are causes or correlates, and whether a mouse eye result licenses statements about human aging. Sinclair's answer has generally been more confident than his colleagues'.
Sinclair did more than any other academic to make aging biology fundable and discussable outside the field, and the reprogramming programme his laboratory helped seed is now among the most heavily capitalized directions in biotechnology. He has also been an effective advocate for the Geroscience hypothesis in policy settings, arguing that aging should be a regulatory indication in its own right. The same visibility supplies the field's critics with their best material, and it has complicated the parallel effort to get surrogate endpoints taken seriously by regulators who now associate the field with overstatement.
Whether the information theory of aging survives as a causal account or is absorbed as one more entry in the hallmarks list depends on experiments — reprogramming delivered systemically to normally aged animals, with lifespan rather than clock readings as the endpoint — that have not yet been reported.
paperSinclair, D. A. and Guarente, L. "Extrachromosomal rDNA circles — a cause of aging in yeast." Cell, 1997. ↩
paperHowitz, K. T. et al. "Small molecule activators of sirtuins extend Saccharomyces cerevisiae lifespan." Nature, 2003.↩The lifespan measurements are in yeast, and the SIRT1 activation was read out with a fluorophore-tagged substrate later argued to produce the effect.
paperBaur, J. A. et al. "Resveratrol improves health and survival of mice on a high-calorie diet." Nature, 2006.↩The survival benefit was in mice fed a high-calorie diet; later work found no lifespan extension in mice on a standard diet.
paperPacholec, M. et al. "SRT1720, SRT2183, SRT1460, and resveratrol are not direct activators of SIRT1." Journal of Biological Chemistry, 2010. ↩
paperGomes, A. P. et al. "Declining NAD+ induces a pseudohypoxic state disrupting nuclear-mitochondrial communication during aging." Cell, 2013. ↩
paperYang, J. H. et al. "Loss of epigenetic information as a cause of mammalian aging." Cell, 2023.↩The mice were engineered to sustain repeated induced double-strand breaks, a severe insult that ordinary aging does not deliver.
paperLu, Y. et al. "Reprogramming to recover youthful epigenetic information and restore vision." Nature, 2020. ↩